Cargando…
Apoptosis-induced ectodomain shedding of hypoxia-regulated carbonic anhydrase IX from tumor cells: a double-edged response to chemotherapy
BACKGROUND: Carbonic anhydrase IX (CA IX) is a tumor-associated, highly active, transmembrane carbonic anhydrase isoform regulated by hypoxia and implicated in pH control and adhesion-migration-invasion. CA IX ectodomain (ECD) is shed from the tumor cell surface to serum/plasma of patients, where it...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4799595/ https://www.ncbi.nlm.nih.gov/pubmed/26993100 http://dx.doi.org/10.1186/s12885-016-2267-4 |
_version_ | 1782422379720343552 |
---|---|
author | Vidlickova, Ivana Dequiedt, Franck Jelenska, Lenka Sedlakova, Olga Pastorek, Michal Stuchlik, Stanislav Pastorek, Jaromir Zatovicova, Miriam Pastorekova, Silvia |
author_facet | Vidlickova, Ivana Dequiedt, Franck Jelenska, Lenka Sedlakova, Olga Pastorek, Michal Stuchlik, Stanislav Pastorek, Jaromir Zatovicova, Miriam Pastorekova, Silvia |
author_sort | Vidlickova, Ivana |
collection | PubMed |
description | BACKGROUND: Carbonic anhydrase IX (CA IX) is a tumor-associated, highly active, transmembrane carbonic anhydrase isoform regulated by hypoxia and implicated in pH control and adhesion-migration-invasion. CA IX ectodomain (ECD) is shed from the tumor cell surface to serum/plasma of patients, where it can signify cancer prognosis. We previously showed that the CA IX ECD release is mediated by disintegrin and metalloproteinase ADAM17. Here we investigated the CA IX ECD shedding in tumor cells undergoing apoptosis in response to cytotoxic drugs, including cycloheximide and doxorubicin. METHODS: Presence of cell surface CA IX was correlated to the extent of apoptosis by flow cytometry in cell lines with natural or ectopic CA IX expression. CA IX ECD level was assessed by ELISA using CA IX-specific monoclonal antibodies. Effect of recombinant CA IX ECD on the activation of molecular pathways was evaluated using the cell-based dual-luciferase reporter assay. RESULTS: We found a significantly lower occurrence of apoptosis in the CA IX-positive cell subpopulation than in the CA IX-negative one. We also demonstrated that the cell-surface CA IX level dropped during the death progress due to an increased ECD shedding, which required a functional ADAM17. Inhibitors of metalloproteinases reduced CA IX ECD shedding, but not apoptosis. The CA IX ECD release induced by cytotoxic drugs was connected to elevated expression of CA IX in the surviving fraction of cells. Moreover, an externally added recombinant CA IX ECD activated a pathway driven by the Nanog transcription factor implicated in epithelial-mesenchymal transition and stemness. CONCLUSIONS: These findings imply that the increased level of the circulating CA IX ECD might be useful as an indicator of an effective antitumor chemotherapy. Conversely, elevated CA IX ECD might generate unwanted effects through autocrine/paracrine signaling potentially contributing to resistance and tumor progression. |
format | Online Article Text |
id | pubmed-4799595 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-47995952016-03-20 Apoptosis-induced ectodomain shedding of hypoxia-regulated carbonic anhydrase IX from tumor cells: a double-edged response to chemotherapy Vidlickova, Ivana Dequiedt, Franck Jelenska, Lenka Sedlakova, Olga Pastorek, Michal Stuchlik, Stanislav Pastorek, Jaromir Zatovicova, Miriam Pastorekova, Silvia BMC Cancer Research Article BACKGROUND: Carbonic anhydrase IX (CA IX) is a tumor-associated, highly active, transmembrane carbonic anhydrase isoform regulated by hypoxia and implicated in pH control and adhesion-migration-invasion. CA IX ectodomain (ECD) is shed from the tumor cell surface to serum/plasma of patients, where it can signify cancer prognosis. We previously showed that the CA IX ECD release is mediated by disintegrin and metalloproteinase ADAM17. Here we investigated the CA IX ECD shedding in tumor cells undergoing apoptosis in response to cytotoxic drugs, including cycloheximide and doxorubicin. METHODS: Presence of cell surface CA IX was correlated to the extent of apoptosis by flow cytometry in cell lines with natural or ectopic CA IX expression. CA IX ECD level was assessed by ELISA using CA IX-specific monoclonal antibodies. Effect of recombinant CA IX ECD on the activation of molecular pathways was evaluated using the cell-based dual-luciferase reporter assay. RESULTS: We found a significantly lower occurrence of apoptosis in the CA IX-positive cell subpopulation than in the CA IX-negative one. We also demonstrated that the cell-surface CA IX level dropped during the death progress due to an increased ECD shedding, which required a functional ADAM17. Inhibitors of metalloproteinases reduced CA IX ECD shedding, but not apoptosis. The CA IX ECD release induced by cytotoxic drugs was connected to elevated expression of CA IX in the surviving fraction of cells. Moreover, an externally added recombinant CA IX ECD activated a pathway driven by the Nanog transcription factor implicated in epithelial-mesenchymal transition and stemness. CONCLUSIONS: These findings imply that the increased level of the circulating CA IX ECD might be useful as an indicator of an effective antitumor chemotherapy. Conversely, elevated CA IX ECD might generate unwanted effects through autocrine/paracrine signaling potentially contributing to resistance and tumor progression. BioMed Central 2016-03-19 /pmc/articles/PMC4799595/ /pubmed/26993100 http://dx.doi.org/10.1186/s12885-016-2267-4 Text en © Vidlickova et al. 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Vidlickova, Ivana Dequiedt, Franck Jelenska, Lenka Sedlakova, Olga Pastorek, Michal Stuchlik, Stanislav Pastorek, Jaromir Zatovicova, Miriam Pastorekova, Silvia Apoptosis-induced ectodomain shedding of hypoxia-regulated carbonic anhydrase IX from tumor cells: a double-edged response to chemotherapy |
title | Apoptosis-induced ectodomain shedding of hypoxia-regulated carbonic anhydrase IX from tumor cells: a double-edged response to chemotherapy |
title_full | Apoptosis-induced ectodomain shedding of hypoxia-regulated carbonic anhydrase IX from tumor cells: a double-edged response to chemotherapy |
title_fullStr | Apoptosis-induced ectodomain shedding of hypoxia-regulated carbonic anhydrase IX from tumor cells: a double-edged response to chemotherapy |
title_full_unstemmed | Apoptosis-induced ectodomain shedding of hypoxia-regulated carbonic anhydrase IX from tumor cells: a double-edged response to chemotherapy |
title_short | Apoptosis-induced ectodomain shedding of hypoxia-regulated carbonic anhydrase IX from tumor cells: a double-edged response to chemotherapy |
title_sort | apoptosis-induced ectodomain shedding of hypoxia-regulated carbonic anhydrase ix from tumor cells: a double-edged response to chemotherapy |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4799595/ https://www.ncbi.nlm.nih.gov/pubmed/26993100 http://dx.doi.org/10.1186/s12885-016-2267-4 |
work_keys_str_mv | AT vidlickovaivana apoptosisinducedectodomainsheddingofhypoxiaregulatedcarbonicanhydraseixfromtumorcellsadoubleedgedresponsetochemotherapy AT dequiedtfranck apoptosisinducedectodomainsheddingofhypoxiaregulatedcarbonicanhydraseixfromtumorcellsadoubleedgedresponsetochemotherapy AT jelenskalenka apoptosisinducedectodomainsheddingofhypoxiaregulatedcarbonicanhydraseixfromtumorcellsadoubleedgedresponsetochemotherapy AT sedlakovaolga apoptosisinducedectodomainsheddingofhypoxiaregulatedcarbonicanhydraseixfromtumorcellsadoubleedgedresponsetochemotherapy AT pastorekmichal apoptosisinducedectodomainsheddingofhypoxiaregulatedcarbonicanhydraseixfromtumorcellsadoubleedgedresponsetochemotherapy AT stuchlikstanislav apoptosisinducedectodomainsheddingofhypoxiaregulatedcarbonicanhydraseixfromtumorcellsadoubleedgedresponsetochemotherapy AT pastorekjaromir apoptosisinducedectodomainsheddingofhypoxiaregulatedcarbonicanhydraseixfromtumorcellsadoubleedgedresponsetochemotherapy AT zatovicovamiriam apoptosisinducedectodomainsheddingofhypoxiaregulatedcarbonicanhydraseixfromtumorcellsadoubleedgedresponsetochemotherapy AT pastorekovasilvia apoptosisinducedectodomainsheddingofhypoxiaregulatedcarbonicanhydraseixfromtumorcellsadoubleedgedresponsetochemotherapy |